Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial

Conclusions: NTHi-Mcat vaccine administered to patients with COPD was immunogenic but did not reduce the yearly rate of moderate/severe exacerbations. No safety concerns were identified. There were fewer reports of COPD leading to hospitalisation in the vaccine group.Funding: GSK

Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Andreas, S., Testa, M., Boyer, L., Brusselle, G., Janssens, W., Kerwin, E., Papi, A., Pek, B., Puente-Maestu, L., Saralaya, D., Watz, H., Wilkinson, T. M., Casula, D., Di Maro, G., Lattanzi, M., Moraschini, L., Schoonbroodt, S., Tasciotti, A., Arora, A. K Tags: Airway pharmacology and treatment Source Type: research